Cytotect®CP found to be safe and effective after allo-HCT

Five responders died within 100 days due to the following causes: GVHD (n = 2), other infection (n = 1), underlying disease (n = 1), and CMV-related causes (n = 1).

Two of the 4 nonresponders died of other infection (n = 1) and GVHD (n = 1).

Investigators estimated the 100-day OS from the start of Cytotect^®CP to be 69.6%. They observed no statistical difference (P=0.258) between those who responded (73.7%) and those who didn’t (50.0%).

The investigators believe that Cytotect^®CP is an alternative option for treatment of CMV infection because it avoids renal and bone marrow impairment and should be considered as prophylaxis in select patients.

They recommend a large prospective study be conducted to confirm safety and efficacy results of CMV hyperimmune globulin.

Cytotect^®CP is authorized in more than 15 countries for the prophylaxis of CMV infection in patients receiving immunosuppressive treatment, particularly transplant recipients.

In French transplant centers, according to the study authors, use of Cytotect^®CP  is limited to the salvage setting for recurrent or refractory CMV infections and sometimes in combination for CMV pneumonia.

Biotest, the commercializer of Cytotect®CP, provided a grant for this study.